Prescribing information

 

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Professor Samreen Ahmed, Dr Raffaele Califano, Dr David Farrugia and CNS, Gemma Shaw review the 5-year data for dabrafenib + trametinib in NSCLC and discuss key learning from their clinical experience of this targeted combination through sharing patient case studies.

“As with the molecular non-small lung cancer paradigm, if we have an actionable mutation, I believe these patients are best served with a targeted agent, and in this case would be a combination of dabrafenib and trametinib”

Dr Raffaele Califano, The Christie and University Hospital of South Manchester

Select the menu within the video to enable you to skip between sections.

 

 


BRAF+, v-raf murine sarcoma viral oncogene homolog B1 positive; NSCLC, non-small cell lung cancer.

Indication: Tafinlar in combination with Mekinist is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.1,2

References

  1. Tafinlar (dabrafenib) GB Summary of Product Characteristics.
  2. Mekinist (trametinib) GB Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | January 2022 | 167724
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]